Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial

• 主要な著者: Yan-Fei Wu (著者), Ming-Wei Wei (著者), Rui-Jie Wang (著者), Xi-Ling Guo (著者), Hong-Xing Pan (著者), Ya-Chun Gao (著者), Xiao-Long Li (著者), Xue Wang (著者), Xiao-Min Ma (著者), Peng Wan (著者), Li Zhou (著者), Ya-Wen Zhu (著者), Jing-Xin Li (著者), Feng-Cai Zhu (著者)
• フォーマット: 図書
• 出版事項: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Background The certification of immunogenicity consistency at different production scales is indispensable for the quality control of vaccines. Research design and methods A randomized, double-blind immunobridging trial in healthy adults aged 18-59 was divided into Scale A (50 L and 800 L) and Scale...